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Aim. To develop a method and obtain proof-of-principle for immunolymphoscintigraphyfor identiﬁcation of metastatic sentinel
nodes.Methods.Weselected oneof four tumour-speciﬁc antibodies againsthumanbreast cancer andinvestigated (1), in immune-
deﬁcient (nude) mice with xenograft human breast cancer expressing the antigen if speciﬁc binding of the intratumorally
injected, radioactively labelled, monoclonalantibody could be scintigraphicallyvisualized, and(2)transportation to andretention
in regional lymph nodes of the radioactively labelled antibody after subcutaneous injection in healthy rabbits. Results and
Conclusion.Ourpaper suggeststhetheoreticalpossibilityofamodelofdualisotopeimmuno-lymphoscintigraphyfornoninvasive,
preoperative, malignantsentinel node imaging.
1.Introduction
The most signiﬁcant prognostic factor in breast cancer,
melanoma, and other solid tumours with primarily lym-
phatic spread is the metastatic status of the regional
lymphnodes.Therefore,identiﬁcationofpossiblesubclinical
regional lymph node metastases is of major importance.
The sentinel node (SN) technique is now widely accepted
as a minimally invasive and accurate method for identify-
ing breast cancer and melanoma patients with subclinical
regional lymph node metastases likely to beneﬁt from
complete regional lymph node dissection (CLND) and pos-
sibly adjuvant therapy. The technique saves approximately
60% of breast cancer patients [1] and 80% of melanoma
patients [2, 3] without regional metastases from the risk of
complications related to CLND. The SN is usually deﬁned
as any lymph node receiving direct lymph from the primary
tumour site, and it is thought to be the entrance for
further regional spread of the cancer, followed by delayed
progression ofmetastases to otherlymph nodesin theregion
[4].
The use of lymphoscintigraphy and subsequent intraop-
erative probe detection and use of blue dye for visual SN
identiﬁcation have improved patient management, morbid-
ity, and probably also mortality. An important limitation of
SN detection is the lack of knowledge before the operation
as to whether the SN contains malignant cells or not. The
retention in the regional lymph nodesofcolloidsused forSN
lymphoscintigraphy only identiﬁes the SN but is not related
to the presence of malignant cells in the SNs. Excision of
an SN, therefore, has to be combined with histology and
immunohistochemistry to identify possible malignant cells.2 International Journal of Molecular Imaging
If malignant tissue in the regional lymph nodes could
be detected preoperatively and noninvasively, permitting
better selection of patients for CLND, the SN technique
would be clinically greatly improved. This could lead to
omission of regional lymph node surgery in node-negative
patients and diminishing the extent of surgery with better
preoperative planning of a one-stage procedure in node-
positive patients. Immunolymphoscintigraphy might rep-
resent such a tool. Immunolymphoscintigraphy refers to
scintigraphy with interstitial (subcutaneous, intracutaneous,
or intratumoral) injection of a tumour-speciﬁc radiolabelled
antibody for malignant lymph node imaging. A variety of
radiolabelled antibodies against tumour-associated antigens
have previously been studied, both in animals and humans,
to test their ability to selectively target cancer cells in lymph
nodes. In the immunoscintigraphy literature, more interest
has been paid to intravenous administration of radiolabelled
antibodies, often with disappointing results [5, 6], though
a few promising studies have been reported [7, 8]. By
intravenous administration of the radiolabelled antibody,
only a small fraction of the antibody gets direct access to
the target, partly due to the distribution of the antibody
in the total blood volume, and partly due to a generally
high and rapid hepatic uptake of foreign proteins. Therefore,
a lymphoscintigraphy approach with interstitial injection
of the antibody appears promising in several diseases for
detection of metastatic regional lymph nodes [9, 10]. Results
reported have been promising, but not yet suﬃciently
eﬃcient for clinical use [11–13]. Will the antibody injected
like a sentinel node radiopharmaceutical pass to the regional
lymph nodes, but only stay there for a limited time interval
permitting binding to the speciﬁc antigen if present on the
surface of tumour cells?
The aim of the study was to develop a method and
obtain proof-of-principle for immunolymphoscintigraphy
for identiﬁcation of metastatic sentinel nodes. To do so we
(1) in vitro tested and selected one of four tumour speciﬁc
antibodies against membrane bound antigens expressed by
human breast cancer, (2) investigated the in vivo antigen-
antibody binding in a xenograft mice model with human
breast cancer, known to express the antigen and with
tumourssized-like humanlymph nodes,and (3)investigated
if radioactively labelled antibodies were transported to and
throughregionallymphnodeswheninjectedsubcutaneously
in healthy rabbits. A strategy to set up dual isotope
immunolymphoscintigraphy for noninvasive, preoperative,
malignant sentinel node diagnosis is ﬁnally suggested.
2.Materialsand Methods
2.1. In Vitro Test of Antibodies on Tissue and Cell Lines.
We tested 4 diﬀerent murine monoclonal antibodies known
to be expressed in human breast cancer; 3 against poly-
morphous epithelial mucin (MUC1), an epithelial trans-
membrane glycoprotein (clone E29 (Dako, Glostrup, Den-
mark), clone GP 1.4 (AbCam, Cambridge, UK), and clone
115D8(Monosan, Uden,The Netherlands)),and oneagainst
epithelial cellular adhesion molecule (EpCam (Calbiochem,
Merck, Darmstadt, Germany)). Binding of the 4 antibodies
to human MCF-7 and MDA-MB-231 breast cancer cells and
lymph nodes with and without metastases were tested by
immunoperoxidase staining using chromogenic identiﬁca-
tion and radioactive labelling with iodide-125(125I)followed
by autoradiography (Figure 1). In brief, tissue sections were
predigested with proteinase-K and incubated with the 125I-
labelled antibody (see below) or nonlabelled antibody at 1–
5μg/mL for one hour and subsequentlywashed several times
with PBS. The tissue sections incubated with the radiola-
belled antibodies were dried in ethanol and immersed into
an autoradiographic emulsion (Ilford Imaging, Knutsford,
UK) and exposed 1–3 days before development. The tissue
sections with nonlabelled antibodies were immunoperoxi-
dase stained using mouse-speciﬁc Envision reagent (Dako,
Glostrup, Denmark) followed by NovaRed chromogen
development (Vector Laboratories, Burlingname, CA, USA).
Among the 4 monoclonal antibodies the anti-MUC1, Clone
115D8, (MON 9005, Monosan, Uden, The Netherlands)
showed the highest signal-to-noise ratio in human breast
tissue sections and stained virtually all MCF-7 cells, and,
therefore, was chosen for in vivo studies.
2.2.Radiolabelling of Anti-MUC1. Anti-MUC1,Clone 115D8,
was presented as puriﬁed IgG at approximately 100μg
IgG/mL in azide-free PBS. Mouse monoclonal antibody
against trinitrophenyl hapten (TNP) [14] diluted in azide-
free PBS was kindly provided by Dr. Gunilla Hoyer-Hansen
(The Finsen Laboratory, Rigshospitalet, Denmark). Iodide-
125 (125I) labelling of anti-MUC1 was used for immuno-
histochemical analyses. Iodide-131 (131I) was chosen for
the ﬁrst series of in vivo studies due to its long half-life.
Iodide-123 (123I) was used in the second series because of
its better energy spectrum for imaging purposes, compared
with 131I. Antibodies were radiolabelled with 123I,125I, and
131I using the iodogen method [15]. Free radioactive iodide
was removed using a Dowex 1 × 8–100 anion exchange
resin. According to thin-layer chromatography of the radi-
olabelled antibodies, radiochemical purity above 95% was
obtained.
2.3. Anti-MUC1/-TNP (123Ia n d131I) In Vivo Studies in Mice.
Two test series were performed in 6-week-old female NMRI
nude mice (n = 21) inoculated with 107 MCF-7 cells
bilaterally in the thigh. One week prior to inoculation with
MCF-7 cells, a 17β-estradiol pellet (0.72mg, 60-day release,
Innovative Research of America, Sarasota, FL, USA) was
implanted subcutaneously in the neck. Upon inoculation,
MCF-7 cells were suspended in an equal amount of Matrigel
(BD Biosciences, Broendby, Denmark) to support growth
of the tumours. When tumours were 0.5–1cm3 in size, the
radioactively labelled antibody was injected intratumorally;
either anti-MUC1 or the nonspeciﬁc anti-TNP as control in
a volume of approximately 50μL with insulin syringe. 131I
was used in 9 mice and 123Ii n1 2m i c e .I nt h e131Is e r i e s ,
each tumour was injected with median 3MBq (range 1–
18) 131I-labelled antibodies. In the 123I series, each tumour
was injected with 10MBq 123I-labelled antibodies. One (123I
series) or 3 (131I series) days after injection, the mice








Figure 1: The ﬁgure shows speciﬁc immunostaining of MCF-7 tumour metastases in human lymph nodes. There is no staining of normal
lymph node tissue; (a and b): immunoperoxidase staining with anti-MUC1 (2 diﬀerent views) (c and d) 125I-immunohisto-autoradiogrphy
with anti-MUC1, (c) bright-ﬁeld, (d) dark ﬁeld.
labelled antibodies was studied on a gamma camera (Pro-
Vivo, Santax Medico, Glostrup, Denmark) with 30 minutes
static images. For 123I, a low-energy, parallel-hole, general-
purpose collimator was used, for 131I, a medium-energy,
parallel-hole, general-purpose collimator was used. In the
131I series, the tumours, thyroid gland, kidneys, liver, and
a foot (reference tissue) were dissected and weighed after 7
days, and ﬁnal imaging and count rates (cps/g tissue) were
determined in a well counter.
2.4. 99mTc-HIG/-Nanocolloid In Vivo Studies in Rabbits.
Four healthy female New Zealand white rabbits (weight
2.5–2.9kg) were anaesthetized with Hypnorm-Dormicum
subcutaneously. Two rabbits were injected subcutaneously
on the front side of each lower leg with 40MBq technetium-
99m-labelled human immunoglobulin G (99mTc-HIG)
(Mallinckrodt, Petten, The Netherlands) and 2 with
40MBq technetium-99m-labelled human albumin nanocol-
loid (99mTc-nanocolloid Nanocoll, Tyco, Rotterdam, The
Netherlands) as control. 99mTc labelling of HIG was chosen
in this pilot study because HIG consists of polyclonal IgG
molecules with a size similar to anti-MUC1 and because a
simple kit for 99mTc labelling exists. Images of the rabbits
were acquired on a 1-headed gamma camera (Mediso
Medical Imaging Systems, Budapest, Hungary) with a low
energy, general-purpose collimator 15 minutes and 1, 2.5,
5, and 22 hours after radioisotope injection (hours p.i.).
Dynamic images (matrix size 256 × 256, 5min. per region)
were used during the ﬁrst 2.5hours p.i. with separate image
acquisition over both injection sites and over the inguinal
lymph nodes. Static images (matrix size 128 × 128, 10min.
per region) were used at 5 and 22hours p.i. with image
acquisition over both injection sites, inguinal lymph nodes
and the abdomen. Regions of interest (ROIs) were drawn
around the injection sites, the inguinal lymph nodes, the
bladder, the kidneys, the liver, and the spinal column. Count
rates were corrected for physical decay and background.
Labelling yield of 99mTc-HIG and 99mTc-nanocolloid were
checked with paper chromatography, and purity above 95%
was obtained.
2.5. Statistics. This study was set up as a proof-of-concept
examination with few animals included in each step. Gener-
ally,thestatistical analysis, istherefore,absentorvery limited
and only nonparametric methods were used.
3.Results
3.1. Cellular In Vitro Tests. Immunohistoautoradiogra-
phy with 125I-anti-MUC1 (Clone 115D8) recognizing the
epithelial-speciﬁc surface protein MUC1 showed the highest
signal-to-noise ratio among 4 monoclonal antibodies tested
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Figure 2: High tumour retention of 131I-anti-MUC1 in a mouse after intratumoral injection (a) and no tumour retention of 131I-anti-TNP
in a mouse after intratumoral injection (b).
Table 1: Count rates per second per gram tissue (cps/g) in diﬀerent tissues from mice in the well counter after injection of 131I-anti-MUC1
or 131I-anti-TNP. The foot is used as a reference region.
Antibody Mouse no. Tumour (cps/g) Foot (cps/g) Thyroid (cps/g) Tumour/foot ratio
131I-anti-MUC1
1 1081 1627 1374 1
2 7050 364 177 19
3 171092 1563 2475 109
4 90395 6546 7401 14
5 22001 2472 2736 89
Median 19
131I-anti-TNP
6 32284 23044 28172 1
7 19526 10932 18764 2
8 14519 2247 2376 6
Median 2
3.2. Tumoral Antibody Retention in Mice. Tumoral retention
of 131I-anti-MUC1 was visualized (Figure 2) with gamma
camera images 72hours p.i. in 2 of 5 mice (one mouse died).
No tumour retention of unspeciﬁc 131I-anti-TNP antibody
was found in any of the 3 control mice. Count rates per
weight tissue (cps/g) determined in the well counter and
calculation of tumour/foot ratio (foot serving as reference
region) showed 131I-anti-MUC1 retention in 4 of the 5 mice
(median 14cps/g, range 1–109) and low tumour retention
of 131I-anti-TNP (median 1cps/g, range 1–6). Furthermore,
uptake of both 131I-anti-MUC1 and 131I-anti-TNP was
s h o w ni nt h et h y r o i dg l a n di na l lm i c e( Table 1).
In the 123I series, gamma camera images showed uncer-
tain tumour retention of 123I-anti-MUC1, comparable with
123I-anti-TNP retention. Diﬀuse uptakein abdominal organs
and high thyroid 123I uptake, as an indirect sign of deiodina-
tion, were seen with both antibodies.
3.3. Lymphatic Drainage of Immunoglobulins and Colloids
in Rabbits. Transport of both 99mTc-HIG and 99mTc-
nanocolloid from the subcutaneous depots towards the
inguinal lymph nodes was observed in the gamma cam-
era images (Figure 3). 99mTc-nanocolloid accumulated over
hours in the lymph nodes with maximum at 22hours
p.i. Gradually, but fairly consistently, some hepatic uptake
was observed. 99mTc-HIG passed more rapidly through the
nodes with maximum at 5hours p.i., and activity gradually
increased in the liver and in the spine (Table 2 and Figure 4,
liver and spine data not shown).
4.Discussion
The two steps of our study strongly suggest that malignant
SNimagingispossible.Usingmicewithhumanbreastcancer
xenografts and gamma camera imaging, we showed the
possibility of noninvasive demonstration of increased reten-
tion of a radiolabelled, tumour-speciﬁc antibody compared
with a nonspeciﬁc radiolabelled antibody. Intratumoral
injection was used in the mouse studies to minimize impact
of changed drainage patterns of xenograft tumours, and
washout was evaluated by determining counts/g in a well
counter of tumours and several organs. Gamma camera
images of the rabbits after subcutaneous injection showed
thatradiolabelled,polyclonalIgGisdrainedbythelymphatic
vessels, but in contrast to the larger colloid particles like
the nanocolloids used for SN imaging, IgG is cleared overInternational Journal of Molecular Imaging 5
Table 2: Mean percentages of activity in rabbit inguinal lymph nodes and liver as a ratio of activity at injection site at diﬀerent times after
injection, calculated from ROIs of the gamma camera images.
Percentage of injected activity (right + left foot) Injection site Inguinal lymph nodes Liver
99mTc-HIG: mean values from 4 rabbit extremities
15min p.i. 100% 0 % 0%
5 hours p.i. 53% 6% 4%
22 hours p.i. 5% 2% 1%
99mTc-nanocolloid: mean values from 4 rabbit extremities
15min p.i. 100% 1% 0%
5 hours p.i. 77% 9% 4%









Figure 3: Visualization on gamma camera images of groin lymph nodes 15min. and 22 hours after injection in rabbits of 99mTc-HIG and
99mTc-nanocolloid, respectively.
hours from regional nonmetastatic lymph nodes. This has
also been shown by others [9, 11, 12]. Finally, our ﬁndings
with 123I-labelled anti-MUC1 demonstrated the well-known
observationthatiodine-labelled antibodiesmaynotbestable
in vivo, in spite of excellent in vitro purity, due to in
vivo deiodination [16]. The diﬀerence between the tumour
retention and higher deiodination of 123I-compared to the
131I-labelled antibody is not obvious. It may be related to
diﬀerence in speciﬁc radioactivities of the iodine-labeled
products.
The appropriate use of radiolabelled antibodies in the
diagnostic evaluation of cancer patients has not yet been
clearly deﬁned. A large number of studies used intravenous
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HIG 1 right H I G1l e f t
HIG 2 right H I G2l e f t
Nanocolloid 1 right Nanocolloid 1 left
Nanocolloid 2 right Nanocolloid 2 left
Figure 4:Uptakeof 99mTc-nanocolloidand 99mTc-HIG inthegroin
lymph nodes of 4 rabbits over time.
sensitivity of successful imaging of malignant tumours with
intravenous administration of radiolabelled antibodies. Due
to the radiation exposure to the body, especially related
to high liver and bone marrow uptake, the radioactive
amount possible to inject intravenously is limited, thereby
limiting the possible fraction taken up by the tumour and
hence target-to-background ratio. Another problem related
to intravenous administration is the risk of a high hepatic
extraction fraction of the antibody [17]. Therefore, the low
count rate of the small fraction of the antibody reaching
the target (lymph nodes) will be too low to visualize
radioactive binding to malignant tissue in the lymph nodes.
Finally, possible cross-reaction with the injected antibody
against circulating antigens [17]might sometimes reducethe
available amount of radiolabelled antibody for binding to
possible malignant tissue in the lymph node.
These problems can be largely circumvented using local
interstitial (subcutaneous, intratumoral, or peritumoral)
injection of the radiolabelled antibody by presenting smaller
amounts of radiolabelled monoclonal antibody closer to the
metastasis, thereby increasing target-to-background ratio.
(Immunoglobulins are macromolecules and when injected
interstitially, preferentially drained by lymphatic vessels
rather than the venous system). They then travel by lymph
vessels to the regional lymph nodes where they can interact
with the cells residing within the node (tumour cells,
lymphocytes, or macrophages). Transit through the lymph
nodes is delayed simply because of their large molecular
size [18]. In contrast, radiocolloid particles used for SN
scintigraphy are trapped within the lymph nodes due to
uptake by macrophages in the lymph nodes [18]. Besides
immunolymphoscintigraphy, interstitial injection of radio-
labelled antibodies also raises the theoretical possibility of
radiotherapy of regional malignant lymph nodes. Both deep
and superﬁcial injection techniques have been shown to be
reliable for SN visualization in breast cancer. However extra
axillary SNs are mainly visualized by intra- or peritumoral
injection, whereas more axillary SNs are visualized by
subcutaneous techniques [19]. A recent study of lymphatic
anatomy on cadavers supports deep injection techniques
[20].
Several diﬀerent isotopes have been used for immuno-
lymphoscintigraphy, each with their advantages and disad-
vantages.Deiodinationinvivoisawell-known problem[16],
as also demonstrated in our 123I mouse series. 111In-labelling
of immunoglobulins may be a better choice than iodine
labelling since 111In-labelled proteins are generally found to
be stable in vivo [21], and the half-life of 2.7 days permits
late imaging. Furthermore, given the energy spectrum of
111In (171 + 245keV) this isotope, rather than the PET
isotopes, could be a good candidate for combined use with
a 99mTc-labelled SN colloid for dual isotope SN imaging
of metastatic inﬁltration of human SNs after local subcuta-
neous injection of both tracers. With the SN identiﬁed by
gamma camera imaging using 99mTc-labelled colloids, the
gamma camera image can be highly focused on the region
and thus much more sensitive, including pinhole collimator
and SPECT or, even better, SPECT-CT images. Given the
results of our mouse and rabbit studies, it might be possible
to create a dual isotope SPECT or SPECT-CT technique
with simultaneous standard SN lymphoscintigraphy and
immunolymphoscintigraphy, which in case of presence of
tumour cells could show tumour-speciﬁc antibody binding
in SNs. If such a technique could be established, it would be
a great improvement of the selection of patients for further
surgery, avoiding SN biopsy in node-negative patients and
directing node-positive patients directly to complete lymph
node dissection. Of course, several issues still remain to
be solved, including a high negative predictive value of the
immunolymphoscintigraphy. The applicability of the tech-
nique will also depend on the minimum size of metastatic
tissue that can be detected. The lower detection limit of
immune-lymphoscintigraphy cannot be known in general
since it will depend on a number of factors including the
amount of antigen present on the surface of the relevant
cancer cells, the binding aﬃnity to the speciﬁc antigen, and
the possible unspeciﬁc binding to other antigens present in
the surrounding tissue, which in turn will determine the
critical signal-to-noise ratio.
The small risk of developing human antimouse antibod-
ies(HAMA)will probablyonly berelevant in patientsreceiv-
ing repeated injections of a murine monoclonal antibody,
which could cause allergic responses and thus primarily
interference with subsequent imaging or results of standard
in vitro laboratory tests, and theoretically also a risk of
anaphylactic complications [22]. Humanized monoclonal
antibodies or small antibody fragments do not elicit a
signiﬁcant humanantihuman (HAHA)response andshould,
therefore, be preferred for clinical use [22], but too small
molecules may be less suited regarding lymphatic drainage.
In addition to the limitation of having performed
experiments only in very few animals, our proof-of-concept
is also limited by the fact that we were not able to test the
concept directly in one animal model, that is, a larger animalInternational Journal of Molecular Imaging 7
with a malignant tumour and metastases to the regional
lymph nodes. Unfortunately, such an animal model was not
available. However, we believed that with this initial proof-
of-concept, a stepwise development could be achieved.
5.Conclusion
131I-labelled anti-MUC1 was found by gamma camera imag-
ing to be retained with high speciﬁcity in xenograft human
breast cancer tumours sized like a human lymph node, after
intratumoral injection. Subcutaneous injection in rabbits
of 99mTc-labelled IgG showed drainage by the lymphatic
vessels, but in contrast to colloids like the nanocolloids used
for SN lymphoscintigraphy, they passed through regional,
nonmetastatic lymph nodes with only limited delay. Iodine
labelled antibodies may be less stable in vivo because
of deiodination. An 111In-labelled tumour antibody might
be a better candidate for a dual isotope technique for
more speciﬁc, noninvasive, preoperative SN diagnosis in
combination with standard 99mTc-SN lymphoscintigraphy.
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